Community Communications

March 2024 – Del-desiran (AOC 1001) MARINA-OLE™ Long-term Data and Phase 3 HARBOR Study

December 2023 – AOC 1044 Healthy Volunteer Data Update

October 2023 – AOC 1001 Data Update

Clinical Studies

MARINA-OLE™ is an open-label, multi-center trial designed to evaluate the long-term safety and tolerability of AOC 1001 in participants with DM1 who were previously enrolled in the MARINA® Phase 1/2 trial. For more information on this study click here or visit http://www.clinicaltrials.gov and search for NCT05479981.

The EXPLORE44™ trial is a randomized, placebo-controlled, double-blind, Phase 1/2 clinical trial to evaluate AOC 1044 in healthy volunteers and participants with DMD mutations amenable to exon 44 skipping (DMD44). For more information on this study click here or visit www.clinicaltrials.gov and search for NCT05670730.

The FORTITUDE™ trial is a randomized, placebo-controlled, double-blind, Phase 1/2 clinical trial designed to evaluate single and multiple doses of AOC 1020 in approximately 70 adult participants with facioscapulohumeral muscular dystrophy (FSHD). For more information on the FORTITUDE study in adults with FSHD and eligibility to participate – FORTITUDE WEBSITE.